A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Profile

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Selinexor (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SADAL
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 02 Nov 2017 According to a Karyopharm Therapeutics media release, the company expects to report top-line results from this trial in the second half of 2018.
    • 23 Jul 2017 According to a Karyopharm Therapeutics media release, updated data from this study will be presented at the 22nd Congress of the European Hematology Association (EHA).
    • 25 Jun 2017 Results (n=72) presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top